Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators ; volume:11 ; number:1 ; day:10 ; month:5 ; year:2023 ; pages:1-22 ; date:12.2023
Acta Neuropathologica Communications ; 11, Heft 1 (10.5.2023), 1-22, 12.2023
- Urheber
-
Segura-Collar, Berta
Hiller-Vallina, Sara
Dios, Olaya de
Caamaño-Moreno, Marta
Mondejar-Ruescas, Lucia
Sepulveda-Sanchez, Juan M.
Gargini, Ricardo
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40478-023-01569-y
- URN
-
urn:nbn:de:101:1-2023101808270299080523
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Segura-Collar, Berta
- Hiller-Vallina, Sara
- Dios, Olaya de
- Caamaño-Moreno, Marta
- Mondejar-Ruescas, Lucia
- Sepulveda-Sanchez, Juan M.
- Gargini, Ricardo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction to: Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models
Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation
NitraTh epitope-based neoantigen vaccines for effective tumor immunotherapy
Neoantigen‐based vaccines as a promising strategy in cancer immunotherapeutics
Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients
Next generation self-replicating RNA vectors for vaccines and immunotherapies
Personalized neoantigen cancer vaccines: current progression, challenges and a bright future
Nanotechnology‐Empowered Combination Cancer Immunotherapies: Mechanisms, Synergies, and Perspectives
Correction: CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies
Alanine-based spacers promote an efficient antigen processing and presentation in neoantigen polypeptide vaccines
Correction to: Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models
Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation
NitraTh epitope-based neoantigen vaccines for effective tumor immunotherapy
Neoantigen‐based vaccines as a promising strategy in cancer immunotherapeutics
Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients
Next generation self-replicating RNA vectors for vaccines and immunotherapies
Personalized neoantigen cancer vaccines: current progression, challenges and a bright future
Nanotechnology‐Empowered Combination Cancer Immunotherapies: Mechanisms, Synergies, and Perspectives
Correction: CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies
Alanine-based spacers promote an efficient antigen processing and presentation in neoantigen polypeptide vaccines
Correction to: Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models
Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation
NitraTh epitope-based neoantigen vaccines for effective tumor immunotherapy
Neoantigen‐based vaccines as a promising strategy in cancer immunotherapeutics
Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients
Next generation self-replicating RNA vectors for vaccines and immunotherapies
Personalized neoantigen cancer vaccines: current progression, challenges and a bright future
Nanotechnology‐Empowered Combination Cancer Immunotherapies: Mechanisms, Synergies, and Perspectives
Correction: CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies